BR112019007901A2 - pirido[3,4-b]indóis substituídos para o tratamento de distúrbios de cartilagem - Google Patents

pirido[3,4-b]indóis substituídos para o tratamento de distúrbios de cartilagem

Info

Publication number
BR112019007901A2
BR112019007901A2 BR112019007901A BR112019007901A BR112019007901A2 BR 112019007901 A2 BR112019007901 A2 BR 112019007901A2 BR 112019007901 A BR112019007901 A BR 112019007901A BR 112019007901 A BR112019007901 A BR 112019007901A BR 112019007901 A2 BR112019007901 A2 BR 112019007901A2
Authority
BR
Brazil
Prior art keywords
pyrido
treatment
cartilage disorders
substituted indoles
cartilage
Prior art date
Application number
BR112019007901A
Other languages
English (en)
Inventor
Gretzke Dirk
Schmidt Friedemann
Ritzeler Olaf
Heinelt Uwe
Wehner Volkmar
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112019007901A2 publication Critical patent/BR112019007901A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção refere-se a 9h-pirido[3,4-b]indóis substituídos por 8-arila e substituídos por 8-heteroarila de fórmula (i), na qual a, e, g, r1 a r6 e r10 são tal como definido nas reivindicações, que estimulam a condrogênese e a síntese da matriz da cartilagem e podem ser usados no tratamento de distúrbios de cartilagem e de condições em que uma regeneração da cartilagem danificada é desejada, por exemplo, doenças das juntas tais como a osteodistrofia. a invenção também se refere aos processos para a síntese dos compostos de fórmula (i), ao seu uso como produtos farmacêuticos, e às composições farmacêuticas que compreendem os mesmos.
BR112019007901A 2016-11-07 2017-11-02 pirido[3,4-b]indóis substituídos para o tratamento de distúrbios de cartilagem BR112019007901A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306452.0A EP3318563A1 (en) 2016-11-07 2016-11-07 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
PCT/EP2017/078026 WO2018083157A1 (en) 2016-11-07 2017-11-02 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Publications (1)

Publication Number Publication Date
BR112019007901A2 true BR112019007901A2 (pt) 2019-07-02

Family

ID=57286428

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007901A BR112019007901A2 (pt) 2016-11-07 2017-11-02 pirido[3,4-b]indóis substituídos para o tratamento de distúrbios de cartilagem

Country Status (35)

Country Link
US (3) US11130755B2 (pt)
EP (3) EP3318563A1 (pt)
JP (1) JP7046063B2 (pt)
KR (1) KR102490199B1 (pt)
CN (1) CN110382496B (pt)
AR (1) AR110136A1 (pt)
AU (2) AU2017353381B2 (pt)
BR (1) BR112019007901A2 (pt)
CA (1) CA3042332A1 (pt)
CL (1) CL2019001251A1 (pt)
CO (1) CO2019005090A2 (pt)
CR (1) CR20190217A (pt)
DK (1) DK3535263T3 (pt)
DO (1) DOP2019000112A (pt)
EA (1) EA038365B1 (pt)
EC (1) ECSP19031458A (pt)
ES (1) ES2837765T3 (pt)
HR (1) HRP20201754T1 (pt)
HU (1) HUE052187T2 (pt)
IL (1) IL265982B (pt)
LT (1) LT3535263T (pt)
MA (1) MA45803B1 (pt)
MX (1) MX2019005308A (pt)
MY (1) MY189589A (pt)
PE (1) PE20191032A1 (pt)
PH (1) PH12019500997A1 (pt)
PT (1) PT3535263T (pt)
RS (1) RS61172B1 (pt)
SG (1) SG11201903195YA (pt)
SI (1) SI3535263T1 (pt)
TN (1) TN2019000143A1 (pt)
TW (1) TWI753966B (pt)
UY (1) UY37473A (pt)
WO (1) WO2018083157A1 (pt)
ZA (1) ZA201902111B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders
EP3717475B1 (en) 2017-11-20 2023-06-07 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3086925A1 (en) 2018-01-05 2019-07-11 Ichan School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
EP3768267A4 (en) * 2018-03-20 2022-04-20 Icahn School of Medicine at Mount Sinai KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
KR20220044721A (ko) * 2019-08-06 2022-04-11 도메인 테라퓨틱스 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물
CN114763347B (zh) * 2021-01-15 2024-06-21 华东师范大学 一类用于诱导间充质干细胞向软骨分化的化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
ECSP951529A (es) 1995-09-05 1997-05-16 Compuestos farmaceuticos
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
JP4599501B2 (ja) 2001-11-07 2010-12-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 多発性骨髄腫および他の癌の処置におけるIκBのインヒビターとしてのカルボリン誘導体
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
JP4626613B2 (ja) * 2004-08-04 2011-02-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子
WO2008023063A2 (en) 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
WO2008132454A1 (en) 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
WO2010038153A1 (en) 2008-10-01 2010-04-08 The University Of British Columbia Use of sox transcription factor acti\ators for stimulating chondrogenesis
EP2455378A1 (en) * 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
JP5854492B2 (ja) 2011-02-24 2016-02-09 国立大学法人 岡山大学 軟骨細胞分化誘導促進剤
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
JP2015107945A (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
EP3318563A1 (en) 2016-11-07 2018-05-09 Sanofi Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders

Also Published As

Publication number Publication date
HRP20201754T1 (hr) 2020-12-25
LT3535263T (lt) 2020-12-28
SG11201903195YA (en) 2019-05-30
MA45803A1 (fr) 2020-05-29
AR110136A1 (es) 2019-02-27
PT3535263T (pt) 2020-12-18
JP7046063B2 (ja) 2022-04-01
EA038365B1 (ru) 2021-08-16
CN110382496A (zh) 2019-10-25
SI3535263T1 (sl) 2020-11-30
EP3318563A1 (en) 2018-05-09
TW201831475A (zh) 2018-09-01
AU2021221468B2 (en) 2023-10-26
JP2019537587A (ja) 2019-12-26
AU2017353381A1 (en) 2019-05-30
US20200095242A1 (en) 2020-03-26
KR20190072654A (ko) 2019-06-25
MY189589A (en) 2022-02-18
DOP2019000112A (es) 2019-07-31
CA3042332A1 (en) 2018-05-11
CO2019005090A2 (es) 2019-07-31
CR20190217A (es) 2019-08-06
CL2019001251A1 (es) 2019-10-04
IL265982A (en) 2019-06-30
MX2019005308A (es) 2019-08-05
TN2019000143A1 (en) 2020-10-05
WO2018083157A1 (en) 2018-05-11
AU2017353381B2 (en) 2021-05-27
MA45803B1 (fr) 2020-10-28
EP3535263A1 (en) 2019-09-11
EP3535263B1 (en) 2020-09-30
US20220041596A1 (en) 2022-02-10
ECSP19031458A (es) 2019-05-31
RS61172B1 (sr) 2021-01-29
HUE052187T2 (hu) 2021-04-28
KR102490199B1 (ko) 2023-01-20
EA201991144A1 (ru) 2019-10-31
CN110382496B (zh) 2022-08-09
UY37473A (es) 2018-06-29
US11130755B2 (en) 2021-09-28
DK3535263T3 (da) 2020-12-21
PH12019500997A1 (en) 2019-08-05
US11827633B2 (en) 2023-11-28
PE20191032A1 (es) 2019-08-05
IL265982B (en) 2021-05-31
US20240182469A1 (en) 2024-06-06
ES2837765T3 (es) 2021-07-01
ZA201902111B (en) 2020-10-28
AU2021221468A1 (en) 2021-09-16
EP3792262A1 (en) 2021-03-17
TWI753966B (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
BR112019007901A2 (pt) pirido[3,4-b]indóis substituídos para o tratamento de distúrbios de cartilagem
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
BR112014030795A2 (pt) composto, composição farmacêutica, uso de um composto e processo para preparação de um composto
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
BR112015011158A2 (pt) triazolopirazina
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112012012906A2 (pt) triazolopiridinas
BR112015017463A8 (pt) Formulação em pó
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112013000275A2 (pt) derivados de tetraidro-pirido-pirimidina
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112017018643A2 (pt) "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas"
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112015012716A2 (pt) derivados de feniletilpiridina como inibidores de pde4
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CY1120744T1 (el) Παραγωγα οξικου οξεος αζαϊνδολης και η χρηση αυτων ως ρυθμιστων υποδοχεων προσταγλανδινης d2
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida
BR112018015191A2 (pt) compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112016018681A2 (pt) implante que compreende fgf-18
EA201992804A1 (ru) Производные аминогликозида и их применение при лечении генетических заболеваний
BR112016021443A8 (pt) Derivados de ácido acético azaindol e seu uso como moduladores de receptor de prostaglandina d2
BR112016002872A2 (pt) derivados de 1 h-pirazolo[3,4-b]piridina e composições farmacêuticas dos mesmos para o tratamento de distúrbios proliferativos

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]